Last update 23 Jan 2025

CaN x Tubulin

Basic Info

Related Targets
CaNTubulin

Related

1
Drugs associated with CaN x Tubulin
Paclitaxel/Pimecrolimus
Target
CaN x FKBP x Tubulin
Mechanism
CaN inhibitors [+3]
Active Org.-
Originator Org.
Novartis Pharma AG
Active Indication-
Inactive Indication
Coronary Artery Disease
Drug Highest PhasePending
First Approval Ctry. / Loc.-
First Approval Date20 Jan 1800
1
Clinical Trials associated with CaN x Tubulin
EUCTR2005-005638-10-DE
/ Not yet recruitingNot Applicable
Evaluation of the antipruritic effect of Elidel (pimecrolimus) in non-atopic pruritic disease
100 Clinical Results associated with CaN x Tubulin
Login to view more data
100 Translational Medicine associated with CaN x Tubulin
Login to view more data
0 Patents (Medical) associated with CaN x Tubulin
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free